A Randomized, Double-blind, Placebo-Controlled, Multiple Doses,Dose-escalationPhase 1b Study of the Safety, TolerabilityPharmacokinetics and the Potential Immunological Reaction of Recombinant Human Thymosin Beta4 in Chinese Healthy Volunteers
Latest Information Update: 30 Sep 2020
At a glance
- Drugs Recombinant human thymosin beta4 Beijing Northland Biotech (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Beijing Northland Biotech
Most Recent Events
- 14 Sep 2020 Status changed from recruiting to completed.
- 26 Oct 2018 New trial record